Zeiss Medical Technology has secured CE mark approval for its Cirrus PathFinder, an AI-driven clinical support tool designed to enhance OCT interpretation and streamline workflows.
The software employs proprietary deep learning algorithms to automatically detect abnormal macular OCT B-scans. It also delivers AI-enhanced OCTA image quality, high-speed image capture, wide field of view, and multi-layer segmentation, enabling ophthalmologists to make more informed and efficient clinical decisions.
Unlike third-party platforms, Cirrus PathFinder integrates directly into the clinician’s workflow, interpreting data in real time and allowing assessment of hundreds of scans simultaneously. It also offers AI-enhanced visualization of vascular structures and improved B-scan averaging to strengthen diagnostic precision.
Zeiss plans to offer Cirrus PathFinder under license through its latest Cirrus software update in select markets.
“At Zeiss, we are committed to advancing digital diagnostics that streamline workflows, reduce costs, and improve patient outcomes,” said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at Zeiss Medical Technology. “The AI capabilities of Cirrus PathFinder enable faster, more actionable diagnostics for a better clinical and patient experience.”